Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details specific transfers of Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- December 7, 2006: Transfer of 17,070 Ordinary Shares.
- December 8, 2006: Transfer of 2,300 Ordinary Shares.
The Company was advised of these transactions on December 11, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop—are interested in the shares held in the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Confirm the total number of shares transferred under the SmithKline Beecham Employee Share Option Plan 1991 during the reporting period.
- Verify the specific interests of Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop in the GSK Trust.
- Review the terms of the GSK Trust to understand the discretionary nature of the beneficiary rights.